Fax: (713) 792-3474
Renal cell carcinoma clinically involving adjacent organs
Experience with aggressive surgical management
Version of Record online: 9 APR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 10, pages 2025–2030, 15 May 2007
How to Cite
Margulis, V., Sánchez-Ortiz, R. F., Tamboli, P., Cohen, D. D., Swanson, D. A. and Wood, C. G. (2007), Renal cell carcinoma clinically involving adjacent organs. Cancer, 109: 2025–2030. doi: 10.1002/cncr.22629
- Issue online: 25 APR 2007
- Version of Record online: 9 APR 2007
- Manuscript Accepted: 13 FEB 2007
- Manuscript Revised: 11 JAN 2007
- Manuscript Received: 12 DEC 2006
- renal cell carcinoma;
- radical nephrectomy;
- tumor staging;
- disease-specific outcome
Historically, patients with nonmetastatic renal cell carcinoma (RCC) involving adjacent organs have been considered inoperable and incurable. The oncologic efficacy of an aggressive surgical approach was evaluated in a selected subpopulation of RCC patients. Further, an attempt was made to define the clinical and pathologic characteristics predictive of surgical failure.
With Institutional Review Board approval, the institutional nephrectomy database of 3470 patients treated at MD Anderson Cancer Center from 1990 to 2006 was searched for RCC patients treated with radical nephrectomy and resection of at least 1 adjacent organ thought to be directly involved by RCC. Patients with nonmetastatic RCC and a minimum follow-up of 6 months were included in the analysis.
In all, 30 patients with clinical T4NxM0 RCC and median follow-up of 32.3 months (range, 8.5–140.1) met the study inclusion criteria and comprise the dataset for the analysis. On pathologic evaluation 60% of patients were clinically overstaged, as only 12 (40%) of 30 patients demonstrated direct invasion into adjacent organs resected. None of the clinical tumor characteristics predicted a finding of pathologic T4 RCC. Nodal involvement and pathologic T stage were significant independent predictors of disease recurrence (hazard ratio [HR] 3.726, P = .043, and HR 2.414, P = .045, respectively) and cancer-specific survival (HR 17.145, P = .002, and HR 3.791, P = .024, respectively). Disease recurred in 11 of 18 (61.1%) of <pT4 patients and in 10 of 12 (83.3%) of pT4 patients at a median 13.3 and 2.3 months, respectively; 13 (73.3%) <pT4 patients and 5 (41.7%) pT4 patients were alive at the time of analysis.
True pathologic involvement of adjacent organs by RCC cannot be predicted from pre- or intraoperative parameters. A significant proportion of patients clinically suspected of having T4 RCC are downstaged, and benefit from aggressive surgical resection with en bloc removal of involved organs. Cancer 2007. © 2007 American Cancer Society.